TaurelFinance, decoded
Live
Loading market data…
TTaurel

Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

MarketWatch· Jaimy Lee· Sep 8, 2026 · 2:37 PM
Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.

This is a summary. Read the complete story at MarketWatch below.

Read full article at MarketWatch

Related Stories

5 really bad reasons to file for Social Security at 70 — are you waiting way too long to get your checks?
marketsabout 5 hours ago

5 really bad reasons to file for Social Security at 70 — are you waiting way too long to get your checks?

Yahoo Finance

Jim Cramer Praises OKTA for Tackling AI Security Threats
marketsabout 5 hours ago

Jim Cramer Praises OKTA for Tackling AI Security Threats

Yahoo Finance

Netskope (NTSK): Eight Analysts Raised Targets on the AI Security Opportunity, But the Cash Burn Is Real
marketsabout 5 hours ago

Netskope (NTSK): Eight Analysts Raised Targets on the AI Security Opportunity, But the Cash Burn Is Real

Yahoo Finance